– USA, KS – Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical today announced the appointments of Curt Medeiros and Gregg Givens to its Board of Directors. Both have officially joined the board in September.
“We are excited to have Curt and Gregg on the Cingulate Board of Directors. Curt’s background in high-growth healthcare companies with relationships across the payer, provider, and life science markets, and Gregg’s two decades of public company finance experience, complement the experience and skills of our current Board and management team. We are benefitting from their fresh perspectives as we continue to advance our innovative product candidates, revitalize patient care and deliver value to our investors” said Chairman and CEO, Dr. Shane Schaffer.
About Curt Medeiros
Curt Medeiros, current CEO and Board member of software company Ovation.io, has more than 20 years of healthcare leadership experience throughout the payer, provider, and life science markets. He worked for nearly 10 years at Optum, a leading information and technology-enabled health services business that is part of UnitedHealth Group, including several leadership roles with significant P&L responsibility. From 2014 to 2016, he served as COO and SVP of Optum Life Sciences, which drives client value by providing best-in-class real-world data, analytics, consulting, and collaborations aimed at improving the health care system for all stakeholders. From 2016 to 2019, Medeiros served as President of both Optum Analytics and Optum Advanced Data & Analytics, overseeing businesses that grew to 1,200 employees and served the analytical needs of external payers, providers, and life science companies.
Most recently, Medeiros served as President and COO of publicly traded Ontrak Inc., a leading AI-powered and telehealth-enabled healthcare company, from December 2019 to June 2021.
“Behavioral health is becoming a high priority for the U.S. and global healthcare system, however, significant challenges persist for patients, physicians, and families living with and caring for individuals with Attention-Deficit/Hyperactivity Disorder,” said Curt Medeiros. “I am impressed with Cingulate’s commitment to this underserved population and progress in developing its two ADHD product candidates, which we believe will simplify the daily management of ADHD, and the future of its broader pipeline. I am deeply committed to Cingulate’s mission and vision and will support the Company’s leadership and talented employees to develop these important treatments and drive growth.”
He has an MBA from Harvard Business School and a B.S. in chemical engineering from the Massachusetts Institute of Technology.
About Gregg Givens
Gregg Givens has more than 35 years of financial and operational leadership experience across the global fintech and healthcare processing, manufacturing, asset management, and real estate industries. For more than two decades, Givens served in finance and accounting leadership roles at DST Systems Inc., a provider of advisory, technology, and operations outsourcing to the financial and healthcare industries, with 16,000 employees worldwide. From 2014 to 2018, Givens served as the SVP, CFO, and Treasurer through its sale to SS&C Technologies. Before DST, Givens, a certified public accountant, worked for nearly 15 years at PricewaterhouseCoopers.
“I am pleased to join the Cingulate Board and believe it has a significant opportunity to address the long-standing unmet needs of patients with ADHD. Cingulate, its product candidates, and drug pipeline are on an exciting trajectory. I look forward to working with the Board and management team to continue executing on Cingulate’s clinical and business milestones for the benefit of patients, employees, and investors,” said Gregg Givens.
He has a BSACC from the University of Missouri-Columbia.
About Cingulate
Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention-Deficit/Hyperactivity Disorder, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
For more information: https://www.cingulate.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.